Loading news...
Sensus Healthcare (NASDAQ: SRTS - Get Free Report) will likely be announcing its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $8.3450 million for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning
Envoy Medical (NASDAQ: COCH - Get Free Report) and Sensus Healthcare (NASDAQ: SRTS - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Risk and Volatility Envoy Medical has a
Sensus Healthcare, Inc. (NASDAQ: SRTS - Get Free Report) has earned a consensus rating of "Hold" from the five brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that management will be meeting with members of the healthcare investment community January 12–14, 2026, in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference. “With recently established coding by the Centers for.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of.
Sensus Healthcare (NASDAQ: SRTS - Get Free Report) and Venus Concept (NASDAQ: VERO - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Analyst Recommendations This is a summary of
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company's global sales, marketing and commercial strategy across its po.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of le.
Sensus Healthcare, Inc. ( SRTS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Joseph Sardano - Co-Founder, Chairman & CEO Michael Sardano - President, General Counsel, Corporate Secretary & Director Javier Rampolla - Chief Financial Officer Conference Call Participants Tirth Patel - Lippert/Heilshorn & Associates, Inc. Anthony Vendetti - Maxim Group LLC, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and welcome to the Sensus Healthcare Third Quarter 2025 Financial Results Conference Call.
Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.07 per share a year ago.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2025. Highlights of the third quarter of 2025 and subsequent weeks include the following: CMS established coding validating SRT for treating non-melanoma skin cancer Revenu.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that it has been named to TIME's list of America's Growth Leaders of 2026, developed in partnership with Statista Inc. The ranking recognizes 500 U.S. publicly traded companies characterized by revenue growth, financial stability and.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the Centers for Medicare & Medicaid Services (CMS) has published a distinct set of treatment codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-melanoma skin cancer (NMSC). SRT-dedicated CPT codes refle.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the passing of longtime friend of the Company and current Director William “Bill” McCall. Bill's involvement with Sensus dates to 2009, when he played a key role in transforming the company from concept to reality. He led the Company's ini.
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the third quarter of 2025 on Thursday, November 6, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer q.
Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $3.31, moving 4.06% from the previous trading session.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Sensus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $3.45, representing a -2.82% change from its previous close.
Sensus Healthcare, Inc. (SRTS) concluded the recent trading session at $3.17, signifying a +2.26% move from its prior day's close.
NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. ("Sensus" or the "Company") (NASDAQ: SRTS).